EUVIMEDEUVIMED entdecken
Crossref

Contemporary use of fibrinolytics in the management of pediatric empyema

Maria Grazia Sacco Casamassima, Janelle R Noel-MacDonnell, Tolulope A Oyetunji, Shawn D St Peter

Pediatric Surgery International · 2024

DOI: 10.1007/s00383-024-05868-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Surgery International, 2024. Verfasst von Maria Grazia Sacco Casamassima und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Children's Mercy Hospital, 2401, Gillham Road, Kansas City, MO, 64108, USA. msaccocasamassim@cmh.edu. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Thoracic Surgery, Video-Assisted, Empyema, Pleural. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study seeks to investigate the contemporary use and effectiveness of fibrinolysis as a first-line option in pediatric empyema. METHODS: The Pediatric Health Information System (PHIS) was queried to identify patients with empyema without fistula (2018-2023). First-line treatments were chest drainage (CD), chest drainage with fibrinolysis (CDF), and video-assisted thoracoscopic surgery/open decortication (VATS/OD). Outcomes between groups were compared using Kruskal-Wallis and Chi-Square tests. Multivariate generalized linear model was used to account for covariates. RESULTS: 581 individuals/cases met inclusion criteria. CD accounted for 11.9% of cases, CDF for 67.6%, and VATS/OD for 20.7%. After adjusting for covariates differences in LOS were not significant (p = 0.393). Subsequent VATS/ODs were required in 6.9% of CDF cases, 8.9% of CD, and 3.3% of primary VATS/OD. Additionally, 32.5% of primary VATS/OD received adjuvant fibrinolysis. Complications were more often observed in the VATS/OD group compared to CD and CDF (11.7% vs 5.8% and 4.1% respectively; p = .008). There were no differences in 30-day readmission rate (VATS/OD:1.2%, CTD:1.5%, and CTDF:1%; p = 0.83). CONCLUSION: Fibrinolysis is now utilized as first-line treatment for most patients and as adjunct in other approaches. The findings justify further implementation as it is the less invasive first-line primary therapy in patients with empyema.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibrinolytic AgentsThoracic Surgery, Video-AssistedEmpyema, PleuralHumansFemaleMaleChildChild, PreschoolRetrospective StudiesInfantAdolescentDrainageTreatment OutcomeThrombolytic Therapy

Stichwörter der Autor:innen

AlteplaseEmpyemaFibrinolysisPHISPleural effusionVATS

Substanzen

Fibrinolytic Agents

Autor:innen und Institutionen

  • Department of Surgery, Children's Mercy Hospital, 2401, Gillham Road, Kansas City, MO, 64108, USA. msaccocasamassim@cmh.edu.
  • Department of Health Services and Outcomes Research, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO, 64108, USA.
  • Department of Surgery, Children's Mercy Hospital, 2401, Gillham Road, Kansas City, MO, 64108, USA.

Zitieren

APA

Sacco Casamassima, M. G., Noel-MacDonnell, J. R., Oyetunji, T. A., & St Peter, S. D. (2024). Contemporary use of fibrinolytics in the management of pediatric empyema. Pediatric Surgery International. https://doi.org/10.1007/s00383-024-05868-w

Vancouver

Sacco Casamassima MG, Noel-MacDonnell JR, Oyetunji TA, St Peter SD. Contemporary use of fibrinolytics in the management of pediatric empyema. Pediatric Surgery International. 2024. doi:10.1007/s00383-024-05868-w

BibTeX
@article{SaccoCasamassima2024,
  author = {Sacco Casamassima, Maria Grazia and Noel-MacDonnell, Janelle R and Oyetunji, Tolulope A and St Peter, Shawn D},
  title = {Contemporary use of fibrinolytics in the management of pediatric empyema},
  journal = {Pediatric Surgery International},
  year = {2024},
  doi = {10.1007/s00383-024-05868-w}
}
Kostenlos starten →